[Treatment of HIV infection from the neurologic viewpoint. Therapy must reach the brain].
An effective highly active antiretroviral therapy (HAART) can prevent the manifestation of HIV-1-associated encephalopathy. Also, HIV-1-associated minor cognitive/motor deficits--an early form of HIV-1-associated dementia--are improved. Clinically manifest HIV-1-associated encephalopathy is an indication for HAART treatment, irrespective of immune status. To date, minor cognitive and/or motor deficits in the presence of good immune status have not been identified as an indication for HAART treatment. Any CNS-effective treatment should be based on either zidovudine or stavudine, since these substances readily enter the CSF; however, NNRTI can also be applied. Side effects of HAART on the central and peripheral nervous system, as well as interactions with known neurological medicaments must be taken into account.
von Giesen
H J
HJ
Neurologische Klinik des Universitätsklinikums, Heinrich-Heine-Universität Düsseldorf. giesenhj@uni-duesseldorf.de
Köller
H
H
Arendt
G
G
D015526:AIDS Dementia Complex / Q000097:blood / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D016896:Treatment Outcome
D019380:Anti-HIV Agents